← Leaderboards
Anne N Murphy
Mitokor
$2,965,764
Attributed
$5,235,925
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $816.6K · FY2007–18$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$5,235,925 · 5
By mechanism
R01$2,925,335 · 1
R42$1,382,487 · 1
P01$588,858 · 1
R21$232,500 · 1
R43$106,745 · 1
Top collaborators
- Geoffrey A Chang5 shared
- Rolf F Kletzien3 shared
- Ana M Pajor1 shared
Others in their field
Top investigators on “Mitochondria”
- Bruce M Spiegelman · Dana-Farber Cancer Inst$30,163,696
- Shi Du Yan · Columbia University Health Sciences$29,685,201
- Peipei Ping · University Of California Los Angeles$27,344,561
- Mary McGrae McDermott · Northwestern University$25,752,019
- Vamsi Krishna Mootha · Massachusetts General Hospital$23,004,991
- Kenneth D. Tew · Fox Chase Cancer Center$22,000,362
Research focus
MitochondriaProgramsBioenergeticsReactive Oxygen SpeciesProductionAreaMutantMetabolicResponseBaseCellsRegulationIn VivoMediatingComplexAcuteAnalogInner Mitochondrial MembraneAdverse EffectsInsulinFeedingDiabetes MellitusDiabeticNon-Insulin-Dependent Diabetes Mellitus
Grant awards (15)
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease$584,104
R01 · FY2018 · NS · contact PI
Metabolic role of the neuronal Na+-dependent citrate transporter implicated in epilepsy$232,500
R21 · FY2018 · NS · contact PI
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease$584,104
R01 · FY2017 · NS · contact PI
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease$584,104
R01 · FY2016 · NS · contact PI
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease$584,104
R01 · FY2015 · NS · contact PI
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease$588,919
R01 · FY2014 · NS · contact PI
PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes$634,311
R42 · FY2011 · DK
CORE D: MITOCHONDRIA: ISOLATION,SUBFRACTIONATION, AND FUNCTIONAL ANALYSIS$117,158
P01 · FY2011 · DK · contact PI
PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes$608,312
R42 · FY2010 · DK
CORE D: MITOCHONDRIA: ISOLATION,SUBFRACTIONATION, AND FUNCTIONAL ANALYSIS$119,419
P01 · FY2010 · DK · contact PI
PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes$139,864
R42 · FY2009 · DK
CORE D: MITOCHONDRIA: ISOLATION,SUBFRACTIONATION, AND FUNCTIONAL ANALYSIS$118,198
P01 · FY2009 · DK · contact PI
CORE D: MITOCHONDRIA: ISOLATION,SUBFRACTIONATION, AND FUNCTIONAL ANALYSIS$118,208
P01 · FY2008 · DK · contact PI
CORE D: MITOCHONDRIA: ISOLATION,SUBFRACTIONATION, AND FUNCTIONAL ANALYSIS$115,875
P01 · FY2007 · DK · contact PI
OSTEOARTHRITIS/CHONDROCALCINOSIS: MITOCHONDRIAL THERAPY$106,745
R43 · FY2003 · AR